A 19-year-old Aboriginal woman from a remote Northern Territory community presents for review of her established rheumatic heart disease with moderate mitral regurgitation. She has a history of definite acute rheumatic fever at age 12. She has been receiving secondary prophylaxis with benzathine benzylpenicillin G 1.2 million units intramuscularly every 4 weeks. She is now planning to move to town where health service access is easier. What is the most appropriate recommendation regarding her secondary prophylaxis?